Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 1. Background and Basis of Presentation
When used in these notes, the terms “Altria,” “we,” “us” and “our” refer to either (i) Altria Group, Inc. and its consolidated subsidiaries or (ii) Altria Group, Inc. only and not its consolidated subsidiaries, as appropriate in the context.
▪Background: At June 30, 2026, our wholly owned subsidiaries included Philip Morris USA Inc. (“PM USA”), which is engaged in the manufacture and sale of cigarettes; John Middleton Co. (“Middleton”), which is engaged in the manufacture and sale of machine-made large cigars and is a wholly owned subsidiary of PM USA; UST LLC (“UST”), which, through its wholly owned subsidiary U.S. Smokeless Tobacco Company LLC (“USSTC”), is engaged in the manufacture and sale of moist smokeless tobacco (“MST”) products; Helix Innovations LLC (“Helix”) and its foreign affiliates (“Helix International”), which are engaged in the manufacture and sale of oral nicotine pouches; and NJOY, LLC (“NJOY”), which is engaged in the manufacture and sale of e-vapor products. We operate primarily within the United States and generate substantially all of our revenue from domestic customers. Other wholly owned subsidiaries included Altria Group Distribution Company (“AGDC”), which provides domestic sales and distribution services to our operating companies, and Altria Client Services LLC (“ALCS”), which provides various support services to our companies in areas such as legal, regulatory, research and product development, consumer engagement, finance, human resources and external affairs. Our access to the operating cash flows of our subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans. At June 30, 2026, our significant subsidiaries were not limited by contractual obligations in their ability to pay cash dividends or make other distributions with respect to their equity interests.
At June 30, 2026, we owned a 75% economic interest in Horizon Innovations LLC (“Horizon”), a joint venture with JTI (US) Holding, Inc. (“JTIUH”), a subsidiary of Japan Tobacco Inc., which owned the remaining 25% economic interest. Horizon is responsible for the U.S. marketing and commercialization of heated tobacco stick products owned by either party. At June 30, 2026, Horizon had no products in the U.S. marketplace.
At June 30, 2026, we had investments in Anheuser-Busch InBev SA/NV (“ABI”) and Cronos Group Inc. (“Cronos”). For further discussion of our investments, see Note 4. Investments in Equity Securities.
▪Basis of Presentation: Our interim condensed consolidated financial statements are unaudited. We have prepared these interim condensed consolidated financial statements in conformity with United States generally accepted accounting principles (“GAAP”) and have applied such principles on a consistent basis. We have omitted certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP. Our management believes that all adjustments necessary for a fair statement of the interim results presented have been reflected in our interim condensed consolidated financial statements. All such adjustments were of a normal recurring nature. Net revenues and net earnings for any interim period are not necessarily indicative of results that may be expected for the entire year.
These condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related notes, which appear in our Annual Report on Form 10-K for the year ended December 31, 2025 (“2025 Form 10-K”).
On January 1, 2026, we adopted Accounting Standards Update (“ASU”) 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets (“ASU No. 2025-05”). This guidance provides a practical expedient for the calculation of current expected credit losses on current accounts receivable and current contract assets that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset. We elected to apply this practical expedient upon adoption of ASU No. 2025-05, which had no impact on our condensed consolidated financial statements.
For a description of issued accounting guidance applicable to, but not yet adopted by, us, see Note 14. New Accounting Guidance Not Yet Adopted.
Note 2. Goodwill and Other Intangible Assets, net
Goodwill and other intangible assets, net, were as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| June 30, 2026 | | December 31, 2025 |
| (in millions) | Goodwill | | Other Intangible Assets, net | | Goodwill | | Other Intangible Assets, net |
| Smokeable products segment | $ | 99 | | | $ | 2,895 | | | $ | 99 | | | $ | 2,909 | |
| Oral tobacco products segment | 5,078 | | | 8,629 | | | 5,078 | | | 8,646 | |
| | | | | | | |
| Other | 610 | | | 326 | | | 610 | | (1) | 321 | |
| Total | $ | 5,787 | | | $ | 11,850 | | | $ | 5,787 | | | $ | 11,876 | |
(1) Comprised of e-vapor reporting unit goodwill related to our 2023 acquisition of NJOY.
Other intangible assets consisted of the following:
| | | | | | | | | | | | | | | | | | | | | | | |
| June 30, 2026 | | December 31, 2025 |
| (in millions) | Gross Carrying Amount | | Accumulated Amortization | | Gross Carrying Amount | | Accumulated Amortization |
Indefinite-lived intangible assets | $ | 11,089 | | | $ | — | | | $ | 11,089 | | | $ | — | |
Definite-lived intangible assets | 1,676 | | | 915 | | | 1,656 | | | 869 | |
| Total other intangible assets | $ | 12,765 | | | $ | 915 | | | $ | 12,745 | | | $ | 869 | |
At June 30, 2026, substantially all of our indefinite-lived intangible assets consisted of (i) MST trademarks of $8.5 billion, which consists of Copenhagen, Skoal and other MST trademarks of $4.0 billion, $3.6 billion and $0.9 billion, respectively, from our 2009 acquisition of UST, and (ii) cigar trademarks of $2.6 billion from our 2007 acquisition of Middleton. Definite-lived intangible assets, consisting primarily of intellectual property, certain cigarette trademarks and customer relationships, are amortized over a weighted-average period of approximately 19 years. Pre-tax amortization expense for definite-lived intangible assets was $46 million and $74 million for the six months ended June 30, 2026 and 2025, respectively, and $23 million and $37 million for the three months ended June 30, 2026 and 2025, respectively.
The changes in goodwill and net carrying amount of intangible assets were as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| For the Six Months Ended June 30, 2026 | | For the Year Ended |
| | December 31, 2025 |
| (in millions) | Goodwill | | Other Intangible Assets, net | | Goodwill | | Other Intangible Assets, net |
Balance at January 1 | $ | 5,787 | | | $ | 11,876 | | | $ | 6,945 | | | $ | 12,973 | |
Changes due to: | | | | | | | |
| Acquisitions | — | | | 20 | | | — | | | 5 | |
Impairments | — | | | — | | | (1,158) | | (1) | (970) | |
Amortization | — | | | (46) | | | — | | | (132) | |
| Balance at end of period | $ | 5,787 | | | $ | 11,850 | | | $ | 5,787 | | | $ | 11,876 | |
(1) Comprised of non-cash goodwill impairments of $873 million and $285 million recorded in the first and fourth quarters of 2025, respectively.
We conduct a required annual review of goodwill and indefinite-lived intangible assets for potential impairment as of October 1 of each year, in accordance with our accounting policy, and more frequently if an event occurs or circumstances change that would require us to perform an interim quantitative impairment assessment. There have been no events or changes in circumstances that indicate an interim quantitative impairment assessment was required as of June 30, 2026.
Our annual impairment test of goodwill and indefinite-lived intangible assets as of October 1, 2025 resulted in a non-cash, pre-tax impairment of $970 million to our e-vapor reporting unit’s definite-lived intangible assets and a non-cash impairment of $285 million to our e-vapor reporting unit goodwill, which we recorded in our consolidated statement of earnings for the year ended December 31, 2025.
At June 30, 2026 and December 31, 2025, accumulated impairment losses related to goodwill were $1,158 million, which related to the e-vapor reporting unit.
First Quarter of 2025 E-vapor Reporting Unit Goodwill Impairment
At December 31, 2024, the carrying value of the e-vapor reporting unit goodwill was $1,768 million. The estimated fair value of the e-vapor reporting unit goodwill exceeded its carrying value by approximately 28% ($0.3 billion). As further discussed in Note 12. Contingencies, Altria and certain of our affiliates, including NJOY, are defendants in lawsuits alleging patent infringement based on the sale of NJOY ACE in the United States. In January 2025, the U.S. International Trade Commission (“ITC”) issued an exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States, which became effective on March 31, 2025. As a result, in connection with the preparation of our condensed consolidated financial statements for the period ended March 31, 2025, we concluded a triggering event had occurred and performed an interim impairment assessment. Based on the results of that assessment, we recorded a non-cash goodwill impairment of $873 million during the three months ended March 31, 2025. This impairment was due primarily to (i) lower projected volume and revenue due to NJOY ACE’s removal from the U.S. market and (ii) higher projected costs associated with the commercialization of NJOY’s future e-vapor product portfolio, resulting in lower projected operating margins. As of March 31, 2025, after recording the impairment, the carrying value of goodwill within the e-vapor reporting unit was $895 million. In addition, the carrying value of the e-vapor reporting unit’s net assets (including the effect of intercompany debt), which was negative, approximated its estimated fair value.
We used an income approach to estimate the fair value of the e-vapor reporting unit. Due to the presence of uncertainties, our cash flows were based on a range of scenarios that consider certain potential regulatory and market outcomes, including the projected impact of enforcement on illicit flavored disposable e-vapor products. In performing the discounted cash flow analyses, we made various judgments, estimates and assumptions, the most significant of which were volume, price, revenue, income, operating margins, scenario weightings, perpetual growth rate and discount rates. We developed these significant assumptions based on our evaluation of the future state of the e-vapor category, including macroeconomic conditions, governmental actions, and other factors, and based these assumptions on factors specific to NJOY’s business. The discount rates used in performing the valuation ranged from 12.0% to 15.0% at March 31, 2025. All significant inputs are classified in Level 3 of the fair value hierarchy.
Note 3. Exit and Implementation Costs
Pre-tax exit and implementation costs consisted of the following:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Exit Costs | | Implementation Costs | | Exit Costs | | Implementation Costs |
| For the Six Months Ended June 30, | | For the Three Months Ended June 30, |
| (in millions) | 2026 | 2025 | | 2026 (1) | 2025 (3) | | 2026 | | 2025 | | 2026 (2) | | 2025 (3) |
| USSTC Facilities Consolidation: | | | | | | | | | | | | | | | |
| Oral tobacco products segment | $ | 19 | | | $ | — | | | $ | 59 | | | $ | — | | | $ | 19 | | | $ | — | | | $ | 59 | | | $ | — | |
Optimize & Accelerate initiative: | | | | | | | | | | | | | | | |
| Smokeable products segment | 2 | | | 1 | | | 12 | | | 25 | | | 2 | | | 1 | | | 7 | | | 12 | |
| Oral tobacco products segment | — | | | — | | | 2 | | | 4 | | | — | | | — | | | 1 | | | 2 | |
Total Optimize & Accelerate initiative | 2 | | | 1 | | | 14 | | | 29 | | | 2 | | | 1 | | | 8 | | | 14 | |
| Total | $ | 21 | | | $ | 1 | | | $ | 73 | | | $ | 29 | | | $ | 21 | | | $ | 1 | | | $ | 67 | | | $ | 14 | |
Amounts are recorded in our condensed consolidated statements of earnings as follows:
(1) Cost of sales ($59 million) and marketing, administration and research costs ($14 million).
(2) Cost of sales ($59 million) and marketing, administration and research costs ($8 million).
(3) Marketing, administration and research costs.
The movement in liabilities related to exit and implementation costs is as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| (in millions) | | Exit Costs | | | | Implementation Costs | | Total | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Balances at December 31, 2024 | | $ | 35 | | | | | $ | 22 | | | $ | 57 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Charges | | 8 | | | | | 48 | | | 56 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Cash paid | | (18) | | | | | (61) | | | (79) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Balances at December 31, 2025 | | 25 | | | | | 9 | | | 34 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Charges (1) | | 21 | | | | | 14 | | | 35 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Cash paid | | (10) | | | | | (14) | | | (24) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Balances at June 30, 2026 | | $ | 36 | | | | (2) | $ | 9 | | | $ | 45 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
(1) Implementation costs exclude non-cash asset-related charges associated with the USSTC Facilities Consolidation discussed below.
(2) Represents liabilities for employee separation costs.
USSTC Facilities Consolidation
In May 2026, we announced our plan to transition USSTC’s manufacturing operations at our Nashville, Tennessee plant to a new facility to be constructed on our existing campus in Hopkinsville, Kentucky (“USSTC Facilities Consolidation”). We expect the consolidation to be substantially completed in the first quarter of 2028.
We estimate total pre-tax charges for the USSTC Facilities Consolidation to be approximately $180 million, consisting of employee separation and other associated costs, which will be paid in cash, as well as certain asset-related charges for inventory and machinery and equipment, which are non-cash charges. For the six and three months ended June 30, 2026, we incurred pre-tax charges of $78 million, which consisted of non-cash asset-related charges ($59 million) and employee separation costs ($19 million). As of June 30, 2026, there have been no cash payments related to the USSTC Facilities Consolidation.
Optimize & Accelerate
In October 2024, we announced a multi-phase Optimize & Accelerate initiative (“Initiative”) designed to modernize our ways of working and enable us to increase our organization’s speed, efficiency and effectiveness by centralizing work, outsourcing certain transactional tasks and streamlining, automating and standardizing processes.
We estimate total pre-tax charges for the Initiative to be approximately $175 million. As of June 30, 2026, total pre-tax charges since the inception of the Initiative were $140 million, consisting of employee separation costs of $45 million and implementation costs of $95 million. We expect to record the majority of the remaining charges by the end of 2027. All of these charges result in cash expenditures and consist of severance payments associated with employee separations, implementation costs for new technology and business advisory services and other costs. As of June 30, 2026, total cash payments since the inception of the Initiative were $114 million, consisting of $28 million for exit costs and $86 million for implementation costs.
Note 4. Investments in Equity Securities
The carrying amount of our investments consisted of the following:
| | | | | | | | | | | | | | |
| (in millions) | | June 30, 2026 | | December 31, 2025 |
| ABI | | $ | 8,577 | | | $ | 8,303 | |
| Cronos | | 319 | | | 314 | |
| | | | |
| Total | | $ | 8,896 | | | $ | 8,617 | |
(Income) losses from our investments in equity securities consisted of the following:
| | | | | | | | | | | | | | | | | | | | | | | | |
| For the Six Months Ended June 30, | | For the Three Months Ended June 30, | |
| (in millions) | 2026 | 2025 | | 2026 | | 2025 |
ABI (1) | $ | (240) | | (2) | $ | (273) | | | $ | (81) | | (2) | $ | (148) | | |
Cronos (1) | (5) | | | (18) | | | (6) | | | — | | |
| (Income) losses from investments in equity securities | $ | (245) | | | $ | (291) | | | $ | (87) | | | $ | (148) | | |
(1) Includes our share of amounts recorded by our investees and additional adjustments, if required, related to (i) the conversion from international financial reporting standards to GAAP and (ii) adjustments to our investments required under the equity method of accounting.
(2) Includes $114 million of pre-tax dilution loss resulting from ABI’s share activity that reduced our ABI ownership interest.
Investment in ABI
At June 30, 2026, we had an approximate 8.1% ownership interest in ABI, consisting of approximately 125 million restricted shares of ABI (“Restricted Shares”) and approximately 34 million ordinary shares of ABI. Our Restricted Shares:
▪are unlisted and not admitted to trading on any stock exchange;
▪are convertible by us into ordinary shares of ABI on a one-for-one basis;
▪rank equally with ordinary shares of ABI with regards to dividends and voting rights; and
▪have director nomination rights with respect to ABI.
We account for our investment in ABI under the equity method of accounting because we have active representation on ABI’s board of directors and certain ABI board committees. Through this representation, we believe we have the ability to exercise significant influence over the operating and financial policies of ABI and participate in ABI’s policy making processes.
We report our share of ABI’s results using a one-quarter lag because ABI’s results are not available in time for us to record them in the concurrent period.
The fair value of our investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI’s ordinary shares and is classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares and is classified in Level 2 of the fair value hierarchy. Because we can convert our Restricted Shares into ordinary shares at our discretion, the fair value of each Restricted Share is based on the value of an ordinary share.
At June 30, 2026, the fair value of our investment in ABI was $13.2 billion, which exceeded its carrying value of $8.6 billion by approximately 54%. At December 31, 2025, the fair value of our investment in ABI was $10.3 billion, which exceeded its carrying value of $8.3 billion by approximately 24%.
Investment in Cronos
At June 30, 2026, we had an approximate 42.2% ownership interest in Cronos, consisting of approximately 157 million shares, which we account for under the equity method of accounting. We report our share of Cronos’s results using a one-quarter lag because Cronos’s results are not available in time for us to record them in the concurrent period.
The fair value of our investment in Cronos is based on unadjusted quoted prices in active markets for Cronos’s common shares and is classified in Level 1 of the fair value hierarchy. At June 30, 2026, the fair value of our investment in Cronos was $432 million, which exceeded its carrying value of $319 million by approximately 35%. At December 31, 2025, the fair value of our investment in Cronos was $411 million, which exceeded its carrying value of $314 million by approximately 31%.
Note 5. Financial Instruments
Our investment in ABI, whose functional currency is the Euro, exposes us to foreign currency exchange risk on the carrying value of our investment. To manage this risk, we may designate Euro denominated unsecured long-term notes (“foreign currency denominated debt”) and certain foreign exchange contracts, including cross-currency swap contracts and forward contracts (collectively, “foreign currency contracts”), as net investment hedges of our investment in ABI. At June 30, 2026 and December 31, 2025, we had no outstanding foreign currency contracts.
The aggregate carrying value and fair value of our total long-term debt were as follows:
| | | | | | | | | | | |
| (in millions) | June 30, 2026 | | December 31, 2025 |
| Carrying value | $ | 24,577 | | | $ | 25,709 | |
| Fair value | 22,815 | | | 24,303 | |
| Foreign currency denominated debt included in long-term debt: | | | |
| Carrying value | 2,566 | | | 2,638 | |
| Fair value | 2,546 | | | 2,619 | |
The fair value of our total long-term debt is based on observable market information derived from a third-party pricing source and is classified in Level 2 of the fair value hierarchy.
Net Investment Hedging
We recognize changes in the carrying value of the foreign currency denominated debt due to changes in the Euro to U.S. dollar exchange rate in accumulated other comprehensive losses related to ABI. We recognized pre-tax (gains) losses of our net investment hedges of $(73) million and $403 million for the six months ended June 30, 2026 and 2025, respectively, and $(30) million and $264 million for the three months ended June 30, 2026 and 2025, respectively.
Contingent Payments
In 2023, we acquired NJOY Holdings, Inc. (“NJOY Transaction”). The total consideration for the NJOY Transaction included the fair value of up to $500 million in additional cash payments contingent on receipt of U.S. Food and Drug Administration (“FDA”) authorizations with respect to NJOY ACE menthol ($250 million, paid in 2024 following FDA authorization), blueberry ($125 million) and watermelon ($125 million) pod products.
The changes in the liability associated with contingent payments were as follows:
| | | | | | | | | | | | |
| For the Six Months Ended June 30, 2026 | | | For the Year Ended December 31, 2025 |
| (in millions) | | |
| Balance at January 1 | $ | 45 | | | | $ | 20 | |
Change in the fair value of contingent payments (1) | — | | | | 25 | |
| | | | |
| Balance at end of period | $ | 45 | | | | $ | 45 | |
(1) These pre-tax charges were recorded in the first quarter of 2025 in marketing, administration and research costs in our condensed consolidated statements of earnings and related to NJOY ACE blueberry and watermelon pod products.
We recognized the liability for contingent payments related to the NJOY Transaction at its estimated fair value as of the acquisition date. We recognize subsequent changes to the fair value in earnings until the contingency is resolved. In determining the estimated fair value, we made certain judgments, estimates and assumptions, the most significant of which was the likelihood of certain potential regulatory outcomes. We classified the liability for contingent payments in Level 3 of the fair value hierarchy.
Note 6. Benefit Plans
Components of Net Periodic Benefit Cost (Income)
Net periodic benefit cost (income) consisted of the following:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Pension | | Postretirement | | Pension | | Postretirement |
| For the Six Months Ended June 30, | | For the Three Months Ended June 30, |
| (in millions) | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 |
| Service cost | $ | 18 | | | $ | 18 | | | $ | 5 | | | $ | 6 | | | $ | 10 | | | $ | 9 | | | $ | 3 | | | $ | 3 | |
| Interest cost | 145 | | | 159 | | | 25 | | | 28 | | | 73 | | | 80 | | | 12 | | | 14 | |
Expected return on plan assets | (198) | | | (215) | | | (2) | | | (2) | | | (99) | | | (108) | | | (1) | | | (1) | |
| Amortization: | | | | | | | | | | | | | | | |
| Net loss (gain) | 48 | | | 25 | | | (5) | | | (6) | | | 24 | | | 12 | | | (2) | | | (3) | |
| Prior service cost (credit) | 3 | | | 2 | | | (20) | | | (20) | | | 2 | | | 1 | | | (10) | | | (10) | |
| | | | | | | | | | | | | | | |
| Net periodic benefit cost (income) | $ | 16 | | | $ | (11) | | | $ | 3 | | | $ | 6 | | | $ | 10 | | | $ | (6) | | | $ | 2 | | | $ | 3 | |
Employer Contributions
We make contributions to our pension plans to the extent that the contributions are tax deductible and pay benefits that relate to plans for salaried employees that cannot be funded under Internal Revenue Service (“IRS”) regulations. We made employer contributions of $8 million to our pension plans and did not make any contributions to our postretirement plans during the six months ended June 30, 2026. Currently, we anticipate making additional employer contributions in 2026 to our pension and postretirement plans of up to approximately $52 million and $100 million, respectively. However, the foregoing estimates of 2026 contributions to our pension and postretirement plans are subject to change as a result of changes in tax and other benefit laws, changes in interest rates and asset performance significantly above or below the assumed long-term rate of return for each respective plan.
Note 7. Earnings per Share
We calculated basic and diluted earnings per share (“EPS”) using the following:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | For the Six Months Ended June 30, | | For the Three Months Ended June 30, |
| (in millions) | | 2026 | | 2025 | | 2026 | | 2025 |
| Net earnings | | $ | 4,481 | | | $ | 3,455 | | | $ | 2,298 | | | $ | 2,378 | |
| Less: Distributed and undistributed earnings attributable to share-based awards | | (11) | | | (10) | | | (6) | | | (7) | |
| Earnings for basic and diluted EPS | | $ | 4,470 | | | $ | 3,445 | | | $ | 2,292 | | | $ | 2,371 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Weighted-average shares for basic and diluted EPS | | 1,672 | | | 1,687 | | | 1,670 | | | 1,684 | |
Unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents are participating securities and, therefore, are included in our EPS calculation pursuant to the two-class method.
Note 8. Other Comprehensive Earnings/Losses
Changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria were as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | For the Six Months Ended June 30, 2026 |
| (in millions) | | Benefit Plans | | ABI | | Currency Translation Adjustments | | Accumulated
Other
Comprehensive
Losses |
| Balances, December 31, 2025 | | $ | (1,415) | | | $ | (1,217) | | | $ | 5 | | | $ | (2,627) | |
| | | | | | | | |
Other comprehensive earnings (losses) before reclassifications | | — | | | 275 | | | (7) | | | 268 | |
| Deferred income taxes | | — | | | (59) | | | 1 | | | (58) | |
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes | | — | | | 216 | | | (6) | | | 210 | |
| | | | | | | | |
| Amounts reclassified to net earnings | | 29 | | | 18 | | | — | | | 47 | |
| Deferred income taxes | | (7) | | | (4) | | | — | | | (11) | |
| Amounts reclassified to net earnings, net of deferred income taxes | | 22 | | | 14 | | | — | | | 36 | |
| | | | | | | | |
| Other comprehensive earnings (losses), net of deferred income taxes | | 22 | | | 230 | | (1) | (6) | | | 246 | |
| | | | | | | | |
| Balances, June 30, 2026 | | $ | (1,393) | | | $ | (987) | | | $ | (1) | | | $ | (2,381) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | For the Three Months Ended June 30, 2026 |
| (in millions) | | Benefit Plans | | ABI | | Currency Translation Adjustments | | Accumulated
Other
Comprehensive
Losses |
Balances, March 31, 2026 | | $ | (1,405) | | | $ | (1,054) | | | $ | 9 | | | $ | (2,450) | |
| | | | | | | | |
Other comprehensive earnings (losses) before reclassifications | | — | |
| 70 | | | (11) | | | 59 | |
| Deferred income taxes | | — | | | (15) | | | 1 | | | (14) | |
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes | | — | | | 55 | | | (10) | | | 45 | |
| | | | | | | | |
| Amounts reclassified to net earnings | | 15 | | | 15 | | | — | | | 30 | |
| Deferred income taxes | | (3) | | | (3) | | | — | | | (6) | |
| Amounts reclassified to net earnings, net of deferred income taxes | | 12 | | | 12 | | | — | | | 24 | |
| | | | | | | | |
| Other comprehensive earnings (losses), net of deferred income taxes | | 12 | | | 67 | | (1) | (10) | | | 69 | |
| | | | | | | | |
| Balances, June 30, 2026 | | $ | (1,393) | | | $ | (987) | | | $ | (1) | | | $ | (2,381) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | For the Six Months Ended June 30, 2025 |
| (in millions) | | Benefit Plans | | ABI | | Currency Translation Adjustments | | Accumulated
Other
Comprehensive
Losses |
| Balances, December 31, 2024 | | $ | (1,392) | | | $ | (1,018) | | | $ | 10 | | | $ | (2,400) | |
| | | | | | | | |
Other comprehensive earnings (losses) before reclassifications | | — | | | (510) | | | (20) | | | (530) | |
| Deferred income taxes | | — | | | 118 | | | — | | | 118 | |
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes | | — | | | (392) | | | (20) | | | (412) | |
| | | | | | | | |
| Amounts reclassified to net earnings | | 4 | | | (28) | | | — | | | (24) | |
| Deferred income taxes | | (1) | | | 6 | | | — | | | 5 | |
| Amounts reclassified to net earnings, net of deferred income taxes | | 3 | | | (22) | | | — | | | (19) | |
| | | | | | | | |
| Other comprehensive earnings (losses), net of deferred income taxes | | 3 | | | (414) | | (1) | (20) | | | (431) | |
| | | | | | | | |
| Balances, June 30, 2025 | | $ | (1,389) | | | $ | (1,432) | | | $ | (10) | | | $ | (2,831) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | For the Three Months Ended June 30, 2025 |
| (in millions) | | Benefit Plans | | ABI | | Currency Translation Adjustments | | Accumulated
Other
Comprehensive
Losses |
Balances, March 31, 2025 | | $ | (1,391) | | | $ | (1,287) | | | $ | (13) | | | $ | (2,691) | |
| | | | | | | | |
Other comprehensive earnings (losses) before reclassifications | | — | | | (179) | | | 3 | | | (176) | |
| Deferred income taxes | | — | | | 45 | | | — | | | 45 | |
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes | | — | | | (134) | | | 3 | | | (131) | |
| | | | | | | | |
| Amounts reclassified to net earnings | | 2 | | | (14) | | | — | | | (12) | |
| Deferred income taxes | | — | | | 3 | | | — | | | 3 | |
| Amounts reclassified to net earnings, net of deferred income taxes | | 2 | | | (11) | | | — | | | (9) | |
| | | | | | | | |
| Other comprehensive earnings (losses), net of deferred income taxes | | 2 | | | (145) | | (1) | 3 | | | (140) | |
| | | | | | | | |
| Balances, June 30, 2025 | | $ | (1,389) | | | $ | (1,432) | | | $ | (10) | | | $ | (2,831) | |
(1) Primarily reflects our share of ABI’s currency translation adjustments and the impact of our designated net investment hedges related to our investment in ABI. For further discussion of designated net investment hedges, see Note 5. Financial Instruments.
Pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings were as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | For the Six Months Ended June 30, | | For the Three Months Ended June 30, |
| (in millions) | | 2026 | | 2025 | | 2026 | | 2025 |
Benefit Plans: (1) | | | | | | | | |
| Net loss | | $ | 46 | | | $ | 22 | | | $ | 23 | | | $ | 11 | |
| Prior service credit | | (17) | | | (18) | | | (8) | | | (9) | |
| | 29 | | | 4 | | | 15 | | | 2 | |
ABI (2) | | 18 | | | (28) | | | 15 | | | (14) | |
| | | | | | | | |
| Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings | | $ | 47 | | | $ | (24) | | | $ | 30 | | | $ | (12) | |
(1) Amounts are included in net periodic benefit income, excluding service cost. For further details, see Note 6. Benefit Plans.
(2) Amounts are included in (income) losses from investments in equity securities.
Note 9. Segment Reporting
At June 30, 2026, our reportable segments were (i) smokeable products, consisting of combustible cigarettes and machine-made large cigars; and (ii) oral tobacco products, consisting of MST products and oral nicotine pouches.
For the year ended December 31, 2025, we concluded that our e-vapor products operating segment met the quantitative threshold for presentation as a reportable segment in accordance with Accounting Standards Codification 280, Segment Reporting (“ASC 280”), as a result of the non-cash impairments of e-vapor reporting unit goodwill and related definite-lived intangible assets recorded in 2025. For further discussion of non-cash impairments, see Note 2. Goodwill and Other Intangible Assets, net. As a result, in our 2025 Form 10-K, we presented e-vapor products as a reportable segment (previously in our all other category) and recast segment information for comparative periods. During the first quarter of 2026, we concluded that the e-vapor products operating segment was not expected to be of continuing significance and did not meet the quantitative thresholds as prescribed under ASC 280 for separate reportable segments. As such, the e-vapor products operating segment is no longer considered a reportable segment, and we included the e-vapor products operating segment results in our all other category for all periods presented.
At June 30, 2026, our all other category included (i) e-vapor products, consisting of our NJOY business; (ii) Horizon; (iii) Helix International; and (iv) other business activities, which primarily consists of research and development (“R&D”) expense related to certain new product platforms and technologies.
Altria’s Chief Executive Officer is our chief operating decision maker (“CODM”). Our measure of segment profitability is segment operating companies income (loss) (“OCI”), which is defined as operating income before general corporate expenses and amortization of intangibles. Our CODM uses OCI for planning, forecasting and evaluating business and financial performance of the segments, including allocating capital and other resources to our segments and evaluating results relative to employee compensation targets. Interest and other debt expense, net, along with net periodic benefit income, excluding service cost, and provision for income taxes are centrally managed at the corporate level and, accordingly, such items are not presented by segment since they are excluded from the measure of segment profitability reviewed by our CODM. We do not disclose information about total assets by segment because such information is not reported to or used by our CODM. Segment goodwill and other intangible assets, net, are disclosed in Note 2. Goodwill and Other Intangible Assets, net.
Segment data were as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| For the Six Months Ended June 30, | | For the Three Months Ended June 30, | | |
| (in millions) | 2026 | | 2025 | | 2026 | | 2025 | | | | |
| Net revenues: | | | | | | | | | | | |
| Smokeable products | $ | 10,150 | | | $ | 9,979 | | | $ | 5,392 | | | $ | 5,357 | | | | | |
| Oral tobacco products | 1,382 | | | 1,407 | | | 713 | | | 753 | | | | | |
| All other | 7 | | | (25) | | | 6 | | | (8) | | | | | |
| Net revenues | $ | 11,539 | | | $ | 11,361 | | | $ | 6,111 | | | $ | 6,102 | | | | | |
| Earnings before income taxes: | | | | | | | | | | | |
| OCI: | | | | | | | | | | | |
| Smokeable products | $ | 5,615 | | | $ | 5,399 | | | $ | 2,942 | | | $ | 2,930 | | | | | |
| Oral tobacco products | 816 | | | 931 | | | 381 | | | 498 | | | | | |
| All other | (153) | | | (1,122) | | | (77) | | | (108) | | | | | |
| Amortization of intangibles | (46) | | | (74) | | | (23) | | | (37) | | | | | |
| General corporate expenses | (140) | | | (116) | | | (87) | | | (53) | | | | | |
| Operating income | 6,092 | | | 5,018 | | | 3,136 | | | 3,230 | | | | | |
| Interest and other debt expense, net | 553 | | | 537 | | | 295 | | | 275 | | | | | |
| Net periodic benefit income, excluding service cost | (4) | | | (29) | | | (1) | | | (15) | | | | | |
| (Income) losses from investments in equity securities | (245) | | | (291) | | | (87) | | | (148) | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| Earnings before income taxes | $ | 5,788 | | | $ | 4,801 | | | $ | 2,929 | | | $ | 3,118 | | | | | |
Smokeable products segment OCI consisted of the following, including expenses under the significant expense principle in accordance with GAAP:
| | | | | | | | | | | | | | | | | | | | | | | | | |
| For the Six Months Ended June 30, | | For the Three Months Ended June 30, |
| (in millions) | 2026 | | 2025 | | 2026 | | 2025 | | |
| Net revenues | $ | 10,150 | | | $ | 9,979 | | | $ | 5,392 | | | $ | 5,357 | | | |
Settlement charges (1) | (1,453) | | | (1,486) | | | (785) | | | (799) | | | |
| Excise taxes on products sold | (1,380) | | | (1,502) | | | (732) | | | (787) | | | |
Other segment items (2) | (1,702) | | | (1,592) | | | (933) | | | (841) | | | |
| Operating companies income | $ | 5,615 | | | $ | 5,399 | | | $ | 2,942 | | | $ | 2,930 | | | |
(1) Represents charges related to State Settlement Agreements included in cost of sales. For additional information, see Health Care Cost Recovery Litigation in Note 12. Contingencies.
(2) Other segment items includes manufacturing, marketing, administration and research costs, FDA user fees and other costs.
For the oral tobacco products segment, we did not identify any expenses under the significant expense principle in accordance with GAAP. Other segment items for our oral tobacco products segment include manufacturing, marketing, administration and research costs and excise taxes on products sold. Total oral tobacco products other segment items were $566 million and $476 million for the six months ended June 30, 2026 and 2025, respectively, and $332 million and $255 million for the three months ended June 30, 2026 and 2025, respectively. The CODM reviews total oral tobacco products segment expenses in the aggregate in conjunction with the review of budget-to-actual OCI variances to manage segment operations.
Details of our depreciation expense and capital expenditures were as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | For the Six Months Ended June 30, | | For the Three Months Ended June 30, |
| (in millions) | 2026 | | 2025 | | 2026 | | 2025 | | |
| Depreciation expense: | | | | | | | | | |
| Smokeable products | $ | 27 | | | $ | 29 | | | $ | 14 | | | $ | 14 | | | |
| Oral tobacco products | 22 | | | 21 | | | 11 | | | 11 | | | |
| General corporate and other | 17 | | | 18 | | | 8 | | | 9 | | | |
| Total depreciation expense | $ | 66 | | | $ | 68 | | | $ | 33 | | | $ | 34 | | | |
| Capital expenditures: | | | | | | | | | |
| Smokeable products | $ | 81 | | | $ | 30 | | | $ | 29 | | | $ | 12 | | | |
| Oral tobacco products | 52 | | | 22 | | | 18 | | | 9 | | | |
| General corporate and other | 17 | | | 18 | | | 10 | | | 11 | | | |
| Total capital expenditures | $ | 150 | | | $ | 70 | | | $ | 57 | | | $ | 32 | | | |
The comparability of OCI for our reportable segments was affected by the following:
▪Exit and Implementation Costs: We recorded exit and implementation costs of $94 million and $30 million for the six months ended June 30, 2026 and 2025, respectively, and $88 million and $15 million for the three months ended June 30, 2026 and 2025, respectively. For further discussion and a breakdown of these costs by segment, see Note 3. Exit and Implementation Costs.
▪Tobacco and Health and Certain Other Litigation Items: We recorded pre-tax charges related to tobacco and health and certain other litigation items as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| For the Six Months Ended June 30, | | For the Three Months Ended June 30, |
| (in millions) | 2026 | | 2025 | | 2026 | | 2025 |
| Smokeable products segment | $ | 69 | | | $ | 40 | | | $ | 67 | | | $ | 4 | |
| General corporate expenses | — | | | 1 | | | — | | | 1 | |
Interest and other debt expense, net | 24 | | | 4 | | | 24 | | | — | |
| Total | $ | 93 | | | $ | 45 | | | $ | 91 | | | $ | 5 | |
We recorded the amounts shown in the table above in our smokeable products segment in marketing, administration and research costs in our condensed consolidated statements of earnings. For further discussion, see Note 12. Contingencies.
Note 10. Debt
Short-term Borrowings and Borrowing Arrangements
At June 30, 2026 and December 31, 2025, we had no short-term borrowings.
We have a $3.0 billion senior unsecured 5-year revolving credit agreement (“Credit Agreement”) that expires on October 24, 2029 and includes an option, subject to certain conditions, for us to extend the term for an additional one-year period. We intend to use any borrowings under our Credit Agreement for general corporate purposes.
At June 30, 2026, we had availability under the Credit Agreement for borrowings of up to an aggregate principal amount of $3.0 billion.
Our Credit Agreement includes various covenants, one of which requires us to maintain a ratio of Consolidated EBITDA (earnings before interest, taxes, depreciation and amortization) to Consolidated Interest Expense of not less than 4.0 to 1.0, calculated for the four most recent fiscal quarters. At June 30, 2026, we were in compliance with our covenants in our Credit Agreement. The terms “Consolidated EBITDA” and “Consolidated Interest Expense,” each as defined in our Credit Agreement, include certain adjustments.
PM USA guarantees any borrowings under our Credit Agreement and any amounts outstanding under our commercial paper program.
Long-term Debt
The aggregate carrying value of our total long-term debt at June 30, 2026 and December 31, 2025 was $24.6 billion and $25.7 billion, respectively.
In February 2026, we repaid in full at maturity our 4.400% senior unsecured notes in the aggregate principal amount of approximately $1.1 billion.
At June 30, 2026 and December 31, 2025, accrued interest on long-term debt of $371 million and $425 million, respectively, was included in other accrued liabilities on our condensed consolidated balance sheets.
For a discussion of the fair value of our long-term debt and the designation of our Euro denominated senior unsecured notes as a net investment hedge of our investment in ABI, see Note 5. Financial Instruments.
Note 11. Income Taxes
The income tax rates for the six and three months ended June 30, 2026 were 22.6% and 21.5%, respectively. The income tax rates for the six and three months ended June 30, 2025 were 28.0% and 23.7%, respectively.
The 5.4% decrease in the income tax rate for the six months ended June 30, 2026 was due primarily to higher tax expense in 2025 related to the non-deductible impairment of the e-vapor reporting unit goodwill and tax benefits related to the effective settlement with the IRS in May 2026 of our audit for the 2017 tax year. The 2.2% decrease in the income tax rate for the three months ended June 30, 2026 was due primarily to tax benefits related to the IRS effective settlement discussed above. For further discussion of the non-deductible impairment, see Note 2. Goodwill and Other Intangible Assets, net.
The settlement discussed above excluded our refund claim for the 2017 tax year, based on the Tax Cuts and Jobs Act of 2017’s removal of downward attribution rules relevant to our investment in ABI. In September 2025, this refund claim was denied, and we are pursuing all available appellate remedies.
Note 12. Contingencies
Legal proceedings covering a wide range of matters are pending or threatened in various United States and foreign jurisdictions against Altria and certain of our subsidiaries, including PM USA and NJOY, as well as our indemnitees. Various types of claims may be raised in these proceedings, including product liability, unfair trade practices, antitrust, tax liability, contraband shipments, patent infringement, employment matters, environmental matters, claims alleging violation of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), claims for contribution and claims of competitors, shareholders or distributors. Legislative action, such as changes to tort law, also may expand the types of claims and remedies available to plaintiffs.
Litigation is subject to uncertainty, and it is possible that there could be adverse developments in pending or future cases. An unfavorable outcome or settlement of pending tobacco-related or other litigation could encourage the commencement of additional litigation. Damages claimed in some tobacco-related and other litigation are or can be significant and, in certain cases, have ranged in the billions of dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrates that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. In certain cases, plaintiffs claim that defendants’ liability is joint and several. In such cases, we may face the risk that one or more co-defendants decline or otherwise fail to participate in the bonding required for an appeal or to pay their proportionate or jury-allocated share of a judgment. As a result, under certain circumstances, we may have to pay more than our proportionate share of any bonding- or judgment-related amounts. Furthermore, in those cases where plaintiffs are successful, we also may be required to pay interest and attorneys’ fees.
Although PM USA historically has been able to obtain required bonds or relief from bonding requirements in order to prevent plaintiffs from seeking to collect judgments while adverse verdicts have been appealed, there remains a risk that such relief may not be obtainable in all cases. This risk has been substantially reduced given that 47 states and Puerto Rico limit the dollar amount of bonds or require no bond at all. However, tobacco litigation plaintiffs have challenged the constitutionality of Florida’s bond cap statute in several cases, and plaintiffs may challenge state bond cap statutes in other jurisdictions as well. Such challenges may include the applicability of state bond caps in federal court. States, including Florida, also may seek to repeal or alter bond cap statutes through legislation. Although we cannot predict the outcome of such challenges, it is possible that our condensed consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome of one or more such challenges.
We record provisions in our condensed consolidated financial statements for pending litigation when we determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. At the present time, while it is reasonably possible that an unfavorable outcome in a case may occur, except to the extent discussed elsewhere in this Note 12. Contingencies: (i) management has concluded that it is not probable that a loss has been incurred in any of the pending cases; (ii) management is unable to estimate the possible loss or range of loss that could result from an unfavorable outcome in any of the pending cases; and (iii) accordingly, management has not provided any amounts in our condensed consolidated financial statements for unfavorable outcomes, if any. Litigation defense costs are expensed as incurred.
We have achieved substantial success in managing litigation. Nevertheless, litigation is subject to uncertainty and significant challenges remain. It is possible that our condensed consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. We believe, and have been so advised by counsel handling the respective cases, that we have valid defenses to the litigation pending against us, as well as
valid bases for appeal of adverse verdicts. We have defended, and will continue to defend, vigorously against litigation challenges. However, we may enter into settlement discussions in particular cases if we believe it is in our best interests to do so.
Judgments Paid and Provisions for Tobacco and Health (Including Engle Progeny Litigation) and Certain Other Litigation Items: The changes in our accrued liability for tobacco and health and certain other litigation items, including related interest costs, for the periods specified below are as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | For the Six Months Ended June 30, | | For the Three Months Ended June 30, |
| (in millions) | | 2026 | | 2025 | | 2026 | | 2025 |
| Accrued liability for tobacco and health and certain other litigation items at beginning of period | | $ | 71 | | | $ | 96 | | | $ | 63 | | | $ | 118 | |
| Pre-tax charges for: | | | | | | | | |
Tobacco and health and certain other litigation (1) | | 69 | |
| 40 | | | 67 | | | 4 | |
| | | | | | | | |
JUUL-related settlements (2) | | 4 | | | 1 | | | 4 | | | 1 | |
| Related interest costs | | 24 | | | 4 | | | 24 | | | — | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Payments | | (12) | | | (46) | | | (2) | | | (28) | |
| Accrued liability for tobacco and health and certain other litigation items at end of period | | $ | 156 | | | $ | 95 | | | $ | 156 | | | $ | 95 | |
| | | | | | | | |
(1) Includes judgments, settlements and fee disputes associated with tobacco and health and certain other litigation.
(2) Includes the settlement of certain e-vapor product litigation relating to JUUL e-vapor products. See E-vapor Product Litigation below for a discussion of these settlements.
The accrued liability for tobacco and health and certain other litigation items, including related interest costs, was included in accrued liabilities and other liabilities on our condensed consolidated balance sheets. Pre-tax charges except for related interest costs were included in marketing, administration and research costs in our condensed consolidated statements of earnings. Pre-tax charges for related interest costs were included in interest and other debt expense, net in our condensed consolidated statements of earnings.
Since October 2004, PM USA has paid judgments and settlements (including related costs and fees) totaling approximately $1.2 billion and interest totaling approximately $245 million as of June 30, 2026. These amounts include payments for Engle progeny judgments (and related costs and fees) totaling approximately $454 million and related interest totaling approximately $62 million.
Security for Judgments: To obtain stays of judgments pending appeal, PM USA has posted various forms of security. As of June 30, 2026, PM USA has posted appeal bonds totaling approximately $10 million, which have been collateralized with restricted cash and are included in assets on our condensed consolidated balance sheets.
Overview of Tobacco-Related Litigation
Types and Number of U.S. Cases: Claims related to tobacco products generally fall within the following categories: (i) smoking and health cases alleging personal injury brought on behalf of individual plaintiffs; (ii) health care cost recovery cases brought by governmental (both domestic and foreign) plaintiffs seeking reimbursement for health care expenditures allegedly caused by cigarette smoking and/or disgorgement of profits; (iii) e-vapor cases alleging violation of RICO, fraud, failure to warn, design defect, negligence, antitrust, patent infringement and unfair trade practices; and (iv) other tobacco-related litigation described below. Plaintiffs’ theories of recovery and the defenses raised in tobacco-related litigation are discussed below.
The table below lists the number of certain tobacco-related cases pending in the United States against us as of:
| | | | | | | | | | | | | | | | | |
| July 27, 2026 | | July 28, 2025 | | July 29, 2024 |
Individual Smoking and Health Cases (1) | 247 | | 195 | | 177 |
| Health Care Cost Recovery Actions | — | | 1 | | 1 |
E-vapor Cases(2) | 24 | | 24 | | 81 |
Other Tobacco-Related Cases (3) | 3 | | 3 | | 3 |
(1) Includes as of July 27, 2026, 41 cases filed in Illinois, eight cases filed in New Mexico, 102 cases filed in Massachusetts, two cases filed in Hawaii, 10 cases filed in the U.S. Virgin Islands, 50 cases filed in Pennsylvania and nine non-Engle cases filed in Florida. Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the Engle class (these Engle progeny cases are discussed below in Smoking and Health Litigation - Engle Progeny Cases).
(2) In May 2023, we reached agreement on terms to resolve the majority of the Multidistrict Litigation lawsuits, and, in March 2024, the court granted final approval of the settlement. Pending final dismissal of these cases, as of July 27, 2026, the remaining cases include 20 individual cases that opted out of the settlement, four class action lawsuits pending in Canada. For further discussion of the Multidistrict Litigation settlement, see E-vapor Product Litigation below.
(3) See Certain Other Tobacco-Related Litigation - “Lights/Ultra Lights” Cases and Other Smoking and Health Class Actions below.
International Tobacco-Related Cases: As of July 27, 2026, Altria is named as a defendant in four e-vapor class action lawsuits in Canada. In July 2026, the court in one of those lawsuits in British Columbia certified a nationwide class of residents who used and directly or indirectly purchased JUUL e-vapor products in Canada for purposes that were primarily personal starting in August 2018. The class seeks compensatory and punitive damages for, among other things, personal injuries allegedly suffered from using JUUL e-vapor products. Altria intends to appeal the class certification order. PM USA is a named defendant in nine health care cost recovery actions in Canada, seven of which also name Altria as a defendant; and PM USA and Altria are named as defendants in six smoking and health class actions filed in various Canadian provinces. See Smoking and Health Litigation - Other Smoking and Health Class Actions below for a discussion of the smoking and health class actions filed in various Canadian Provinces. Also, see Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement (defined below) between Altria and PMI that provides for indemnities for certain liabilities concerning tobacco products.
Tobacco-Related Cases Set for Trial: As of July 27, 2026, one Engle progeny case, one individual smoking and health cases and no e-vapor cases are set for trial through September 30, 2026. Trial dates are subject to change.
Trial Results: Since January 1999, excluding the Engle progeny cases (separately discussed below), verdicts have been returned in 88 tobacco-related cases in which PM USA was a defendant. Verdicts in favor of PM USA and other defendants were returned in 54 of the 88 cases. Of the 34 non-Engle progeny cases in which verdicts were returned in favor of plaintiffs, 29 have reached final resolution.
See Smoking and Health Litigation - Engle Progeny Trial Results below for a discussion of verdicts in state and federal Engle progeny cases involving PM USA as of July 27, 2026.
Smoking and Health Litigation
Overview: Plaintiffs’ allegations of liability in smoking and health cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, nuisance, breach of express and implied warranties, breach of special duty, conspiracy, concert of action, violations of unfair trade practice laws and consumer protection statutes and claims under the federal and state anti-racketeering statutes. Plaintiffs in the smoking and health cases seek various forms of relief, including compensatory and punitive damages, treble/multiple damages and other statutory damages and penalties, creation of medical monitoring and smoking cessation funds, disgorgement of profits, and injunctive and equitable relief. Defenses raised in these cases include lack of proximate cause, assumption of the risk, comparative fault and/or contributory negligence, statutes of limitations and preemption by the Federal Cigarette Labeling and Advertising Act.
Non-Engle Progeny Litigation: The charts below summarize the verdicts in and post-trial status of certain non-Engle progeny smoking and health cases in which verdicts were returned in favor of plaintiffs. The first chart lists cases that are pending as of July 27, 2026 where PM USA has recorded a provision in its condensed consolidated financial statements because we have determined that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. The second chart lists cases that are pending as of July 27, 2026 where PM USA has determined an unfavorable outcome is not probable and the amount of loss cannot be reasonably estimated, and the third chart lists cases that have concluded in the past 12 months where PM USA paid a final judgment. In this Note 12. Contingencies, references to “R.J. Reynolds” are to R.J. Reynolds Tobacco Company. Unless otherwise noted for a particular case, the jury’s award for compensatory damages will not be reduced by any finding of plaintiff’s comparative fault. Further, the damages noted reflect adjustments based on post-trial or appellate rulings. A chart listing certain verdicts for plaintiffs in pending Engle progeny cases can be found in Smoking and Health Litigation - Engle Progeny Trial Results below.
Currently Pending Non-Engle Cases with Accrued Liabilities
(rounded to nearest $ million)
| | | | | | | | | | | | | | | | | | | | | | | |
| Plaintiff | Verdict Date | Defendant(s) | State | Compensatory Damages (1) | Punitive Damages
(PM USA) | Post-Trial Status | Accrual(1) |
| Fontaine | September 2022 | PM USA | MA | $8 million | $56 million | The Massachusetts Supreme Judicial Court affirmed the judgment. PM USA intends to seek review by the U.S. Supreme Court. | $89 million |
(1) Accrual amounts include interest and associated costs, if applicable. For any cases with multiple defendants, accrual amounts reflect the portion of compensatory damages PM USA believes it will have to pay if the case is ultimately decided in plaintiff’s favor after taking into account any portion potentially payable by the other defendant.
Currently Pending Non-Engle Cases with Verdicts against PM USA
(rounded to nearest $ million)
| | | | | | | | | | | | | | | | | | | | |
| Plaintiff | Verdict Date | Defendant(s) | State | Compensatory Damages (1) | Punitive Damages
(PM USA) | Post-Trial Status |
| Petruzziello | November 2025 | PM USA R.J. Reynolds | MA | <$1 million | $0 | Plaintiff has filed a notice of appeal. |
| Perez-Trinidad | October 2025 | PM USA R.J. Reynolds | MA | $1 million | $5.5 million | PM USA and R.J. Reynolds have filed notices of appeal. |
| Amaral | March 2025 | PM USA R.J. Reynolds | MA | $4 million | $25 million | PM USA and R.J. Reynolds have filed notices of appeal. |
| Ricapor-Hall | August 2023 | PM USA | HI | $6 million ($3 million) | $8 million | PM USA’s appeal and plaintiff’s cross-appeal remain pending. In April 2025, the Hawaii Supreme Court granted plaintiff’s application to transfer the appeal to that Court from the Intermediate Court of Appeals. |
(1) PM USA’s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies.
Non-Engle Cases Concluded in Past 12 Months
(rounded to nearest $ million)
| | | | | | | | | | | | | | |
| Plaintiff | Verdict Date | Defendant(s) | State | Payment Amount for Damages (if any) |
| Woodley | August 2023 | PM USA | MA | $5 million |
| Taylor | August 2024 | PM USA | OR | <$1 million |
Engle Progeny Cases: Engle progeny cases are individual smoking and health lawsuits filed by Florida resident plaintiffs against one or more cigarette manufacturer defendants. The lawsuits arose following the Florida Supreme Court’s decertification of the class in Engle, et. al. v. R.J. Reynolds Tobacco Co., et. al., a smoking and health class action lawsuit filed in Florida state court against multiple defendants, including PM USA, in which the jury returned a verdict in favor of the plaintiff class and the trial court assessed punitive damages against the defendants. In July 2006, the Florida Supreme Court mandated that the trial court’s punitive damages award be vacated, that the class approved by the trial court be decertified and that members of the decertified class could file individual actions against defendants within one year of issuance of the mandate. Plaintiffs in Engle progeny lawsuits are entitled to rely on certain liability findings from the class action lawsuit, substantially reducing each plaintiff’s burden of proof. These liability findings stipulate: (i) that smoking causes various diseases; (ii) that nicotine in cigarettes is addictive; (iii) that defendants’ cigarettes were defective and unreasonably dangerous; (iv) that defendants concealed or omitted material information not otherwise known or available knowing that the material was false or misleading or failed to disclose a material fact concerning the health effects or addictive nature of smoking; (v) that defendants agreed to conceal or omit information regarding the health effects of cigarettes or their addictive nature with the intention that smokers would rely on the information to their detriment; (vi) that defendants sold or supplied cigarettes that were defective; and (vii) that defendants were negligent.
Pending Engle Progeny Cases: The deadline for filing Engle progeny cases expired in January 2008, at which point a total of approximately 9,300 federal and state claims were pending. As of July 27, 2026, approximately 43 state court cases were pending against PM USA or Altria. Each federal Engle progeny case has been resolved.
Engle Progeny Trial Results: As of July 27, 2026, 148 federal and state Engle progeny cases involving PM USA have resulted in verdicts. Eighty-eight were returned in favor of plaintiffs, four of which have been reversed post-trial or on appeal and remain pending. Sixty verdicts were returned in favor of PM USA. In addition, there have been a number of mistrials, only some of which have resulted in new trials as of July 27, 2026.
Post-trial activity in a case can result in a final resolution that differs from the initial verdict. In many cases, parties have appealed either compensatory or punitive damages awards or both. Courts also have increased and decreased the amounts of compensatory damages juries have awarded, decreased the amounts of punitive damages juries have awarded, declared mistrials and vacated judgments, in whole or in part, with respect to compensatory and punitive damages awards. Initial verdicts have been reversed in whole or in part on appeal or following retrial. Juries have returned verdicts in favor of or against PM USA awarding no damages. In cases where juries returned verdicts against PM USA awarding no damages, some trial courts have decided to award plaintiff damages notwithstanding the verdict. Cases also have been dismissed with or without prejudice before or after a verdict.
The charts below list the verdicts in and post-trial status of certain Engle progeny cases in which verdicts were returned in favor of plaintiffs. The first chart lists cases that are pending as of July 27, 2026 where PM USA has determined an unfavorable outcome is not probable and the amount of loss cannot be reasonably estimated, and the second chart lists cases that have concluded in the past 12 months. Unless otherwise noted for a particular case, the jury’s award for compensatory damages will not be reduced by any finding of plaintiff’s comparative fault. Further, the damages noted reflect adjustments based on post-trial or appellate rulings.
Currently Pending Engle Cases with Verdicts against PM USA
(rounded to nearest $ million)
| | | | | | | | | | | | | | | | | | | | |
| Plaintiff | Verdict Date | Defendant(s) | Court | Compensatory Damages | Punitive Damages
(PM USA) | Post-Trial Status |
| Garcia | June 2024 | PM USA | Miami-Dade | $2 million | $10 million | Appeals to the Third District Court of Appeal pending. |
Engle Cases Concluded in Past 12 Months
(rounded to nearest $ million)
| | | | | | | | | | | | | | |
| Plaintiff | Verdict Date | Defendant(s) | Court | Payment Amount for Damages (if any) |
| Chacon | October 2023 | PM USA | Miami-Dade | $1 million |
| McCall | October 2023 | PM USA | Broward | <$1 million |
Other Smoking and Health Class Actions: Since the dismissal in May 1996 of a purported nationwide class action brought on behalf of allegedly addicted smokers, plaintiffs have filed numerous putative smoking and health class action suits in various state and federal courts. In general, these cases have purported to be brought on behalf of residents of a particular state or states (although a few cases have purported to be nationwide in scope) and have raised addiction claims and, in many cases, claims of physical injury as well.
Class certification has been denied or reversed by courts in approximately 60 smoking and health class actions involving PM USA. See Certain Other Tobacco-Related Litigation below for a discussion of “Lights” and “Ultra Lights” class action cases and medical monitoring class action cases pending against PM USA.
As of July 27, 2026, PM USA and Altria are named as defendants, along with other cigarette manufacturers, in six class actions filed in the Canadian provinces of Alberta, Manitoba, Nova Scotia, Saskatchewan and British Columbia. In Saskatchewan and British Columbia (two separate cases), plaintiffs seek class certification on behalf of individuals who suffer or have suffered from various diseases, including chronic obstructive pulmonary disease, emphysema, heart disease or cancer, after smoking defendants’ cigarettes. In the actions filed in Alberta, Manitoba and Nova Scotia, plaintiffs seek certification of classes of all individuals who smoked defendants’ cigarettes. In March 2019, all of these class actions were stayed as a result of three Canadian tobacco manufacturers (none of which is related to us) seeking protection under Canada’s Companies’ Creditors Arrangement Act (which is similar to Chapter 11 bankruptcy in the United States). The companies entered into these proceedings following a Canadian appellate court upholding two smoking and health class action verdicts against those companies totaling approximately CAD $13 billion. In August 2025, a plan for those companies was implemented, under which those companies agreed, among other things, to pay an aggregate global settlement amount of CAD $32.5 billion to resolve all tobacco product-related claims and litigation in Canada. Under the plan, Altria and PM USA have obtained releases of claims and the related litigation against them will be dismissed. Pursuant to the indemnification obligations in the Distribution Agreement, neither Altria nor PM USA is responsible for any payments required to resolve the Canadian litigation. See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement between Altria and PMI, which provides for indemnities for certain liabilities concerning tobacco products.
Health Care Cost Recovery Litigation
Overview: In the health care cost recovery litigation, governmental entities seek reimbursement of health care cost expenditures allegedly caused by tobacco products and, in some cases, of future expenditures and damages. Relief sought by some but not all plaintiffs includes punitive damages, multiple damages and other statutory damages and penalties, injunctions prohibiting alleged marketing and sales to minors, disclosure of research, disgorgement of profits, funding of anti-smoking programs, additional disclosure of nicotine yields, and payment of attorney and expert witness fees.
Although there have been some decisions to the contrary, most judicial decisions in the United States have dismissed all or most health care cost recovery claims against cigarette manufacturers. Nine federal circuit courts of appeals and eight state appellate courts, relying primarily on grounds that plaintiffs’ claims were too remote, have ordered or affirmed dismissals of health care cost recovery actions. The U.S. Supreme Court has refused to consider plaintiffs’ appeals from the cases decided by five federal circuit courts of appeal.
In addition to the cases brought in the United States, health care cost recovery actions have been brought against tobacco industry participants, including PM USA and Altria, in Canada (nine cases), and other entities have stated that they are considering filing such actions.
Since the beginning of 2008, the Canadian Provinces of British Columbia, New Brunswick, Newfoundland and Labrador, Quebec, Alberta, Manitoba, Saskatchewan, Prince Edward Island and Nova Scotia have brought health care reimbursement claims against cigarette manufacturers. PM USA is named as a defendant in the British Columbia and Quebec cases, while both Altria and PM USA are named as defendants in the New Brunswick, Newfoundland and Labrador, Alberta, Manitoba, Saskatchewan, Prince Edward Island and Nova Scotia cases. The Nunavut Territory and Northwest Territory have passed legislation permitting similar claims, but lawsuits based on this legislation have not been filed. All of these cases were stayed pending resolution of proceedings in Canada involving three tobacco manufacturers (none of which are affiliated with us) under the Companies’ Creditors Arrangement Act discussed above. As
discussed above, in August 2025, a plan for those companies was implemented. See Smoking and Health Litigation - Other Smoking and Health Class Actions above for a discussion of these proceedings. See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement between Altria and PMI that provides for indemnities for certain liabilities concerning tobacco products.
Settlements of Health Care Cost Recovery Litigation: In November 1998, PM USA and certain other tobacco product manufacturers entered into the Master Settlement Agreement (the “MSA”) with 46 states, the District of Columbia and certain United States territories to settle asserted and unasserted health care cost recovery and other claims. PM USA and certain other tobacco product manufacturers had previously entered into agreements to settle similar claims brought by the States of Mississippi, Florida, Texas and Minnesota (together with the MSA, the “State Settlement Agreements”). The State Settlement Agreements require that the original participating manufacturers or “OPMs” (now PM USA, R.J. Reynolds and, with respect to certain brands, ITG Brands, LLC (“ITG”)) make annual payments of approximately $10.4 billion, subject to adjustments for several factors, including inflation, market share and industry volume. For the six months ended June 30, 2026 and 2025, the aggregate amount recorded in cost of sales with respect to the State Settlement Agreements was approximately $1.5 billion for each period. These amounts include PM USA’s estimate of amounts related to NPM Adjustments discussed below.
Non-Participating Manufacturer (“NPM”) Adjustment Disputes: The “NPM Adjustment” is a reduction in MSA payments made by the OPMs and those manufacturers that are subsequent signatories to the MSA (collectively, the “participating manufacturers” or “PMs”) that applies if the PMs collectively lose at least a specified level of market share to non-participating manufacturers since 1997, subject to certain conditions and defenses. The applicability of this reduction has been subject to certain disputes, some of which have been resolved via settlement, as discussed below.
Settlements of NPM Adjustment Disputes.
▪Multi-State Settlement. As of December 2025, a total of 39 states and territories had joined the multi-state settlement. Pursuant to this settlement, PM USA has received $1.57 billion since 2014 and expects to receive annual credits applied against PM USA’s MSA payments through 2041.
▪New York Settlement. In 2015, PM USA entered into a separate NPM Adjustment settlement in which PM USA settled the NPM Adjustment disputes with the State of New York in perpetuity. PM USA has received $723 million pursuant to the New York settlement and expects to receive annual credits applied against the MSA payments due to the State of New York going forward.
▪Montana Settlement. In 2020, PM USA entered into a separate NPM Adjustment settlement in which PM USA settled the NPM Adjustment disputes with the State of Montana through 2030, resulting in a payment from PM USA to the State of Montana for an insignificant amount.
▪Massachusetts Settlement. In 2024, PM USA entered into a separate NPM Adjustment settlement in which PM USA settled the NPM Adjustment disputes with the Commonwealth of Massachusetts through 2011. As a result of this settlement, PM USA received $28 million as a credit against its April 2026 MSA payment to the Commonwealth of Massachusetts. PM USA recorded $28 million as a reduction in costs of sales in the third quarter of 2024.
▪Washington Settlement. In 2025, PM USA entered into a separate NPM Adjustment settlement in which PM USA settled the NPM Adjustment disputes with the State of Washington through 2015. As a result of this settlement, PM USA received $53 million as a credit against its April 2026 MSA payment to the State of Washington. In addition to the amounts recorded in the fourth quarter of 2023 discussed below in connection with the 2005 through 2007 NPM Adjustments, PM USA recorded a $22 million reduction in costs of sales and $4 million of interest expense in the fourth quarter of 2025.
▪U.S. Territories Settlement. In 2025, PM USA entered into a separate NPM Adjustment settlement in which PM USA settled the NPM Adjustment disputes with American Samoa, Guam, the Commonwealth of the Northern Mariana Islands and the U.S. Virgin Islands through 2024. As a result of this settlement, PM USA received a credit in an insignificant amount applied against its April 2026 MSA payment to those territories. PM USA recorded an insignificant amount as a reduction in cost of sales in the third quarter of 2025.
Continuing NPM Adjustment Disputes with States That Have Not Settled.
▪2004 NPM Adjustment. The PMs and 10 states that had not settled the NPM Adjustment disputes for 2004 participated in a multi-state arbitration. The arbitration panel found three of these states (Washington, Missouri and New Mexico) were not diligent in the enforcement of their escrow statutes in 2004, and PM USA received approximately $52 million on account of the 2004 NPM Adjustment as a credit against its April 2023 MSA payment. The State of New Mexico challenged the determination in its state court, and the trial court vacated the award. PM USA appealed, and the New Mexico Court of Appeals reinstated the award.
▪2005-2007 NPM Adjustments. The PMs and six states that had not settled the NPM Adjustment disputes are currently arbitrating certain NPM Adjustment disputes before a single arbitration panel. The arbitration encompasses three years, 2005 through 2007, for five of the six states, and one year, 2005, for one state. As of July 27, 2026, the arbitration panel found the States of Maryland, Wisconsin and Ohio diligent for all three years, the State of Washington not diligent for all three years and the State of Missouri not
diligent for 2005. The State of Washington subsequently settled, as discussed above. PM USA recorded $14 million as a reduction in costs of sales and $21 million as interest income in the fourth quarter of 2023 for its estimate of the minimum amount of the 2005 through 2007 NPM Adjustments it will receive related to the Washington finding. PM USA recorded an insignificant amount as a reduction in cost of sales in the first quarter of 2026 related to the Missouri finding. The State of Missouri has challenged the arbitration panel’s determination for 2005 in state court.
▪Subsequent Years. No assurance can be given as to when proceedings for 2008 and subsequent years will be scheduled or the precise form those proceedings will take.
Other Disputes under the State Settlement Agreements: The payment obligations of the tobacco product manufacturers that are parties to the State Settlement Agreements, as well as the allocations of any NPM Adjustments and related settlements, have been and may continue to be affected by R.J. Reynolds’s acquisition of Lorillard Tobacco Company in 2015 and its related sale of certain cigarette brands to ITG (the “ITG transferred brands”). PM USA continues to dispute how the ITG transferred brands are treated in allocating the NPM Adjustments and profit adjustments under the State Settlement Agreements.
In December 2019, the State of Mississippi filed a motion in Mississippi state court seeking to enforce the Mississippi State Settlement Agreement against PM USA, R.J. Reynolds and ITG concerning the tax rates used in the annual calculation of the net operating profit adjustment payments starting in 2018. In September 2024, PM USA and the State of Mississippi settled their dispute over the profit adjustment payments. Pursuant to the settlement, PM USA paid $7 million to the State of Mississippi for 2018 through 2023. Accordingly, PM USA recorded $5 million of expense to cost of sales and $2 million of interest expense in the third quarter of 2024.
In May 2023, PM USA and R.J. Reynolds filed a motion in the U.S. District Court for the Eastern District of Texas seeking to enforce the Texas State Settlement Agreement against the State of Texas concerning the same tax rate issue raised by the State of Mississippi. The State of Texas filed a cross-motion to enforce, and the court found in favor of the State of Texas. In March 2025, the court issued a final order in the matter, finding that PM USA owes $31 million to the State of Texas, plus pre- and post-judgment interest. PM USA has appealed, and the appeal remains pending.
In July 2024, the State of Minnesota filed a motion in Minnesota state court seeking to enforce the Minnesota State Settlement Agreement against PM USA, R.J. Reynolds and ITG concerning the same tax rate issues raised by the States of Mississippi and Texas. The court found in favor of the State of Minnesota. In October 2025, the court issued an order as to damages, finding that PM USA owes the State of Minnesota $10 million plus pre- and post-judgment interest. PM USA has appealed, and the appeal remains pending.
E-vapor Product Litigation
We have been named as defendants in federal class action lawsuits, individual lawsuits and “third party” lawsuits relating to JUUL e-vapor products, which include school districts, state and local governments and tribal and healthcare organization lawsuits. We refer to this litigation in the United States collectively as the “Multidistrict Litigation.” The theories of recovery in the Multidistrict Litigation include violation of RICO, fraud, failure to warn, design defect, negligence, public nuisance and unfair trade practices. Plaintiffs seek various remedies, including compensatory and punitive damages, restitution or remediation (for plaintiffs that are government entities) and an injunction prohibiting product sales. We also have been named as defendants in a group of cases pending in a consolidated California state court proceeding.
In May 2023, we reached agreement on terms to resolve the majority of the Multidistrict Litigation lawsuits as well as the majority of the group of cases pending in the consolidated California state court proceeding for $235 million, for which amount we recorded a pre-tax provision in the second quarter of 2023. In March 2024, the court granted final approval of the class action settlement, and we paid the settlement amount in the second quarter of 2024. The settlement applies to all of the Multidistrict Litigation except 11 individual cases that opted out of the settlement, all of the consolidated California cases except nine individual cases that opted out of the settlement and 38 “third party” cases brought by Native American tribes. We separately agreed to settle the cases brought by Native American tribes in July 2024, and these cases have been dismissed. We recorded a pre-tax provision for $20 million in the second quarter of 2024 related to the Native American tribes settlement and paid the settlement amount in October 2024. In the second quarter of 2026, we recorded an additional pre-tax provision for $4 million related to the same settlement and paid that amount in July 2026. Neither settlement applies to four class action lawsuits pending in Canada or 17 putative class action antitrust lawsuits. For a description of the class action lawsuits pending in Canada and the class action antitrust lawsuits, in each case not subject to the settlement, see International Tobacco-Related Cases above and Antitrust Litigation below, respectively.
E-vapor Patent Litigation
JUUL Patent Litigation: In June 2023, JUUL and VMR Products LLC (“VMR”) filed a lawsuit against Altria and our affiliates AGDC, ALCS, NJOY Holdings, Inc. (“NJOY Holdings”) and NJOY in the U.S. District Court for the District of Arizona asserting claims of patent infringement based on the sale of NJOY ACE in the United States. Plaintiffs seek various remedies, including damages and an injunction on sales of NJOY ACE. The lawsuit is currently stayed.
Also in June 2023, the same plaintiffs filed a related action against the same defendants with the ITC. There, the plaintiffs also allege patent infringement, but the remedies sought include an exclusion order that would prohibit the importation of NJOY ACE into the United States. No damages are recoverable in the proceedings before the ITC. In January 2025, following an initial determination by
the Administrative Law Judge (“ALJ”), the ITC issued its final determination finding that NJOY ACE infringes the four patents plaintiffs asserted and issued an exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States. The orders became effective on March 31, 2025. We have appealed the orders to the U.S. Court of Appeals for the Federal Circuit. The orders will remain in effect during the pendency of the appeal.
In November and December 2023 and February 2024, Altria and our affiliates filed petitions with the U.S. Patent Office Patent Trial and Appeal Board (“PTAB”) challenging the validity of the patents underlying JUUL and VMR’s patent infringement claims. In May, June and August 2024, the PTAB denied Altria’s requests to institute review as to four patents (including three of the patents that form the basis of the ITC’s final determination) and, in June 2024, granted Altria’s request to institute review as to one of the patents that forms the basis of the ITC’s final determination. In June 2025, the PTAB issued its decision concluding that the patent it reviewed was valid. We have appealed the PTAB’s decision to the U.S. Court of Appeals for the Federal Circuit.
In August 2023, NJOY filed a complaint against JUUL in the U.S. District Court for the District of Delaware asserting claims of patent infringement based on the sale of certain JUUL e-vapor products, including the currently marketed JUUL device and JUULpods, in the United States. The lawsuit was stayed pending the final determination of an ITC investigation NJOY filed against JUUL in August 2023 (discussed below). In October 2025, after the final determination of the corresponding ITC investigation, NJOY moved to lift the stay, and the court granted the motion. JUUL subsequently moved to re-stay the case, which was denied. Trial currently is set for June 2027.
Also in August 2023, NJOY filed a related action against JUUL with the ITC alleging patent infringement and seeking a ban on the importation and sale of the same JUUL products in the United States. In December 2024, the ALJ issued an initial determination concluding that, while the patents NJOY asserted against JUUL are valid, JUUL products do not infringe the patents. On review, the ITC affirmed the ALJ’s initial determination that the JUUL products do not infringe the asserted patents and terminated the investigation. In May 2025, we appealed the ITC’s final determination to the U.S. Court of Appeals for the Federal Circuit. Subsequently, in July 2025, we voluntarily dismissed the appeal and, in October 2025, moved to lift the stay on NJOY’s lawsuit against JUUL in the U.S. District Court for the District of Delaware (discussed above).
In November 2023, JUUL filed petitions with the PTAB challenging the validity of the patents underlying NJOY’s patent infringement claims. In May 2024, the PTAB agreed to review JUUL’s challenge to both of the NJOY patents asserted against JUUL. In May 2025, the PTAB issued its decision concluding that the patents it reviewed were valid. The deadline to appeal the PTAB’s decision has passed, and JUUL did not appeal.
In August 2025, JUUL filed an additional lawsuit against Altria and our affiliates AGDC, ALCS, NJOY Holdings and NJOY in the U.S. District Court for the District of Arizona asserting claims of patent infringement based on the sale of NJOY Daily in the United States. Plaintiff seeks various remedies, including damages and an injunction on sales of NJOY Daily and any other products NJOY may be developing or preparing for commercialization in the United States that would infringe JUUL’s patent.
Also in August 2025, JUUL filed a related action against the same defendants with the ITC. There, JUUL also alleges patent infringement, but the remedies sought include an exclusion order that would prohibit the importation into the United States of NJOY Daily and any other products NJOY may be developing or preparing for commercialization in the United States that would infringe JUUL’s patent. No damages are recoverable in the proceedings before the ITC. In April 2026, the ALJ granted NJOY’s motion for summary determination, finding that the sole patent that forms the basis of JUUL’s action is invalid. JUUL petitioned the ITC to review the ALJ’s initial determination, and the ITC granted review in May 2026. The ITC has not issued its final determination.
In November 2025, Altria, AGDC, ALCS, NJOY Holdings and NJOY sued the ITC and the ALJ in the U.S. District Court for the Eastern District of Virginia, seeking to enjoin the ITC and ALJ from adjudicating JUUL’s action. The lawsuit asserts that Altria and our affiliates are entitled to have JUUL’s claims heard in a federal court and be tried to a jury, and that the ALJ is unconstitutionally appointed and shielded from removal by the President. Altria and our affiliates have moved for summary judgment and a preliminary injunction. In June 2026, the U.S. District Court for the Eastern District of Virginia denied the motion for a preliminary injunction, and we have appealed that decision to the U.S. Court of Appeals for the Fourth Circuit. Also in November 2025, NJOY Holdings and NJOY filed a petition with PTAB challenging the validity of the patent underlying JUUL’s August 2025 actions. In April 2026, PTAB issued a discretionary denial of that petition, refusing to reach the merits of whether JUUL’s patent is valid.
In September 2025, NJOY, ALCS, and AGDC filed an action against JUUL with the ITC alleging patent infringement and seeking a ban on the importation and sale of the same JUUL products in the United States. A hearing before the ALJ is scheduled for September 2026, and we expect an initial determination from the ALJ in December 2026, subject to the ALJ’s ability to grant himself an extension. The ALJ’s recommendation will be reviewed by the ITC, and we expect the ITC’s final determination in April 2027, subject to the ITC’s ability to grant itself an extension.
R.J. Reynolds Patent Litigation: ALCS filed a lawsuit against R.J. Reynolds in the U.S. District Court for the Middle District of North Carolina alleging patent infringement by R.J. Reynolds’ e-vapor products. In September 2022, a jury awarded ALCS $95 million in damages for past infringement, plus supplemental damages and interest. In January 2023, the court ordered R.J. Reynolds to pay ALCS a 5.25% royalty on future sales of its infringing product resulting in positive net income through the expiration of the relevant patents in 2035. R.J. Reynolds filed a notice of appeal of the judgment to the U.S. Court of Appeals for the Federal Circuit, which affirmed the
judgment in December 2024. In August 2025, R.J. Reynolds petitioned the U.S. Supreme Court to review the federal appellate court’s affirmance of the federal district court’s judgment. In October 2025, the U.S. Supreme Court denied R.J. Reynolds’ petition.
In July 2024, R.J. Reynolds moved the district court to vacate the judgment, including the damages awards and ongoing royalties, on the grounds that R.J. Reynolds obtained a sublicense to the asserted patents from JUUL in December 2023. In December 2024, the district court denied the motion as to the damages award and royalties due through December 2023. The district court also found that additional proceedings were warranted on the part of the motion regarding royalties after R.J. Reynolds obtained the sublicense. The district court’s evidentiary hearing occurred in April 2026. Any gains related to this lawsuit remain subject to these district court proceedings. Accordingly, they have not yet been determined to be realized or realizable in accordance with GAAP and have not been recognized in our condensed consolidated financial statements.
Antitrust Litigation
In March 2023, we entered into a stock transfer agreement with JUUL pursuant to which, among other things, we transferred to JUUL all of our beneficially owned JUUL equity securities.
As of July 27, 2026, 17 putative class action lawsuits have been filed against Altria and JUUL in the U.S. District Court for the Northern District of California. In November 2020, these lawsuits were consolidated into three complaints (one on behalf of direct purchasers, one on behalf of indirect purchasers and one on behalf of indirect resellers). The consolidated lawsuits, as amended, allege that Altria and JUUL violated Sections 1, 2 and/or 3 of the Sherman Antitrust Act of 1890 and Section 7 of the Clayton Antitrust Act and various state antitrust and consumer protection laws by restraining trade and/or substantially lessening competition in the U.S. closed-system electronic cigarette market. Plaintiffs seek various remedies, including treble damages, attorneys’ fees, a declaration that the agreements between Altria and JUUL are invalid and rescission of the transaction. In February 2024, the court ordered that certain of the direct-purchaser plaintiffs’ claims against JUUL be sent to arbitration pursuant to an arbitration provision in JUUL’s online purchase agreement and dismissed without prejudice the direct-purchaser plaintiffs’ claims for injunctive relief. In April 2025, plaintiffs voluntarily dismissed all monopolization claims and all claims against the Altria defendants under California’s Unfair Competition Law. In February 2026, the U.S. District Court for the Northern District of California certified three classes of plaintiffs (one of direct purchasers, one of indirect purchasers and one of indirect resellers). In March 2026, Altria and JUUL filed a petition with the Ninth Circuit Court of Appeals seeking discretionary review of the class certification decision, which the court granted in April 2026. The trial with respect to the remaining claims in the consolidated lawsuits will not occur earlier than five months after the Ninth Circuit issues its decision.
Certain Other Tobacco-Related Litigation
“Lights/Ultra Lights” Cases and Other Smoking and Health Class Actions: Plaintiffs have sought certification of their cases as class actions, alleging among other things, that the uses of the terms “Lights” and/or “Ultra Lights” constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment or breach of warranty, and have sought injunctive and equitable relief, including restitution and, in certain cases, punitive damages. These class actions have been brought against PM USA and, in certain instances, Altria or our other subsidiaries, on behalf of individuals who purchased and consumed various brands of cigarettes. Defenses raised in these cases include lack of misrepresentation, lack of causation, injury and damages, the statute of limitations, non-liability under state statutory provisions exempting conduct that complies with federal regulatory directives, and the First Amendment. Twenty-one state courts in 23 “Lights” cases have refused to certify class actions, dismissed class action allegations, reversed prior class certification decisions or have entered judgment in favor of PM USA. As of July 27, 2026, two “Lights/Ultra Lights” class actions are pending in U.S. state courts. Neither case is active.
As of July 27, 2026, one smoking and health case alleging personal injury or seeking court-supervised programs or an ongoing medical monitoring program on behalf of individuals exposed to environmental tobacco smoke and purporting to be brought on behalf of a class of individual plaintiffs, is pending in a U.S. state court. The case is currently inactive.
Environmental Regulation
Altria and our former subsidiaries are subject to various federal, state and local laws and regulations concerning the discharge of materials into the environment, or otherwise related to environmental protection, including, in the United States: the Clean Air Act, the Clean Water Act, the Resource Conservation and Recovery Act and the Comprehensive Environmental Response, Compensation and Liability Act (commonly known as “Superfund”), which can impose joint and several liability on each responsible party. Altria and our former subsidiaries are involved in several cost recovery/contribution cases subjecting them to potential costs of remediation and natural resource damages under Superfund or other laws and regulations. We expect to continue to make capital and other expenditures in connection with environmental laws and regulations.
We provide for expenses associated with environmental remediation obligations on an undiscounted basis when such amounts are probable and can be reasonably estimated. Such accruals are adjusted as new information develops or circumstances change. Other than those amounts, it is not possible to reasonably estimate the cost of any environmental remediation and compliance efforts that we may undertake in the future. In the opinion of our management, however, compliance with environmental laws and regulations, including the
payment of any remediation costs or damages and the making of related expenditures, has not had a material adverse effect on our condensed consolidated results of operations, capital expenditures, financial position or cash flows.
Guarantees and Other Similar Matters
In the ordinary course of business, we have agreed to indemnify a limited number of third parties in the event of future litigation. Additionally, we provide certain guarantees to a limited number of third parties related to contractual obligations. At June 30, 2026, we had $43 million of unused letters of credit obtained in the ordinary course of business. These items have not had, and are not expected to have, a significant impact on our liquidity.
Under the terms of a distribution agreement between Altria and PMI (“Distribution Agreement”), entered into as a result of our 2008 spin-off of our former subsidiary PMI, liabilities concerning tobacco products will be allocated based in substantial part on the manufacturer. PMI will indemnify Altria and PM USA for liabilities related to tobacco products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA will indemnify PMI for liabilities related to tobacco products manufactured by PM USA, excluding tobacco products contract manufactured for PMI. We do not have a related liability recorded on our condensed consolidated balance sheet at June 30, 2026 as the fair value of this indemnification is insignificant.
As part of our supplier financing program, Altria guarantees the financial obligations of ALCS under the financing program agreement.
PM USA guarantees our obligations under our outstanding debt securities, any borrowings under our $3.0 billion Credit Agreement and any amounts outstanding under our commercial paper program.
Note 13. Additional Financial Statement Information
Share Repurchases
In January 2025, our Board of Directors (“Board” or “Board of Directors”) authorized a $1.0 billion share repurchase program that it expanded to $2.0 billion in October 2025. At June 30, 2026, we had $665 million remaining under this program, which expires on December 31, 2026. Share repurchases depend on marketplace conditions and other factors, and the program remains subject to the discretion of our Board.
Our share repurchase activity was as follows:
| | | | | | | | | | | | | | | | | | | | | | | | |
| For the Six Months Ended June 30, | | | For the Three Months Ended June 30, |
| (in millions, except per share data) | 2026 |
| 2025 | | | 2026 | | 2025 |
| Total number of shares repurchased | 5.3 | | | 10.4 | | | | 0.8 | | | 4.7 | |
| Aggregate cost of shares repurchased | $ | 335 | | | $ | 600 | | | | $ | 55 | | | 274 | |
| Average price per share of shares repurchased | $ | 62.78 | | | $ | 57.71 | | | | $ | 65.11 | | | $ | 58.63 | |
Cash, Cash Equivalents and Restricted Cash
A reconciliation of cash, cash equivalents and restricted cash on our condensed consolidated balance sheets to the amounts reported in our condensed consolidated statements of cash flows is as follows:
| | | | | | | | | | | |
| June 30, 2026 | | December 31, 2025 |
| Cash and cash equivalents | $ | 2,367 | | | $ | 4,474 | |
| Restricted cash included in other current assets | — | | | 7 | |
| Restricted cash included in other assets | 14 | | | 11 | |
| Cash, cash equivalents and restricted cash | $ | 2,381 | | | $ | 4,492 | |
Restricted cash consisted primarily of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 12. Contingencies.
Receivables
We record receivables net of the cash discounts on our condensed consolidated balance sheets. At June 30, 2026, December 31, 2025 and December 31, 2024, receivables were $306 million, $263 million and $177 million, respectively.
Deferred Revenue
We record deferred revenue when our businesses receive payment in advance of product shipment, which we include in other accrued liabilities on our condensed consolidated balance sheets until revenue is recognized, and our companies typically satisfy their performance obligations within three days of receiving payment. At June 30, 2026, December 31, 2025 and December 31, 2024, deferred revenue was $145 million, $231 million and $215 million, respectively. At June 30, 2026, December 31, 2025 and December 31, 2024, there were no differences between amounts recorded as deferred revenue from contracts with customers and amounts subsequently recognized as revenue.
Supplier Financing
We facilitate a voluntary supplier financing program through a third-party intermediary under which participating suppliers may elect to sell receivables due from us to participating third-party financial institutions at the sole discretion of both the suppliers and the financial institutions. At June 30, 2026 and December 31, 2025, confirmed outstanding obligations under the supplier financing program, which are recorded in accounts payable on our condensed consolidated balance sheets, were $171 million and $159 million, respectively.
Note 14. New Accounting Guidance Not Yet Adopted
The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, us:
| | | | | | | | | | | |
| Standards | Description | Effective Date for Public Entity | Effect on Financial Statements |
| ASU Nos. 2024-03 and 2025-01 Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses | The guidance will require additional disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. | The guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. | We are in the process of evaluating the impact of this guidance on our disclosures. |
| ASU No. 2025-06 Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software | The guidance replaces the current framework that is based on software development project stages with updated criteria, focused on management’s authorization and the probability of project completion, to determine the timing for cost capitalization. | The guidance is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years. | We are in the process of evaluating the impact of this guidance on our consolidated financial statements and related disclosures. |
| ASU No. 2025-07 Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract | The guidance refines the scope of Topic 815 by excluding from derivative accounting non-exchange trading contracts that have underlyings based on operations or activities specific to one of the parties to the contract with certain exceptions and clarifies the applicability of Topic 606 to share-based noncash consideration received from a customer in exchange for goods or services. | The guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within those fiscal years. | We are in the process of evaluating the impact of this guidance on our consolidated financial statements and related disclosures. |
| ASU No. 2025-09 Derivatives and Hedging (Topic 815): Hedge Accounting Improvements | The guidance includes expanding eligibility for cash flow hedges of groups of forecasted transactions, introducing a model for hedging forecasted interest payments on “choose-your-rate” debt instruments, permitting designation of variable price components in forecasted purchases or sales of nonfinancial assets and clarifying guidance for net investment hedges and dual hedge strategies. | The guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within those fiscal years. | We are in the process of evaluating the impact of this guidance on our consolidated financial statements and related disclosures. |
| ASU No. 2025-11 Interim Reporting (Topic 270): Narrow-Scope Improvements | The guidance clarifies interim disclosure requirements, provides a comprehensive list of disclosures required by GAAP and includes a disclosure principle for events since the last annual reporting period to enhance consistency in interim reporting. | The guidance is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. | We are in the process of evaluating the impact of this guidance on our interim condensed consolidated financial statements and related disclosures. |
| ASU No. 2025-12 Codification Improvements | The guidance provides changes that clarify, correct errors or make minor improvements to GAAP. | The guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within those fiscal years. | We are in the process of evaluating the impact of this guidance on our consolidated financial statements and related disclosures. |